Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters











Database
Language
Publication year range
1.
Int Heart J ; 61(6): 1311-1314, 2020 Nov 28.
Article in English | MEDLINE | ID: mdl-33191338

ABSTRACT

Although some researches proved the influence of radiation therapy (RT) on pacemakers and implantable cardioverter defibrillators, little has been reported on cardiac resynchronization therapy defibrillators (CRTDs). We experienced a case of RT on CRTD and had a new finding.A patient with CRTD implanted for dilated cardiomyopathy was diagnosed with lung squamous cell carcinoma and started receiving RT. All the implanted devices, including the main body of CRTD, left ventricular lead (LV), right ventricular lead with high-voltage conductor, and right atrial lead, were from the same manufacturer. The radiation targeted the tumor of 67 mm in diameter in the right superior lobe for 5 min per session. The CRTD was outside the radiation field, which is 65 mm, but the leads were inside. Plan 1 used 2 Gy/fr with 8 megavolt photons, and Plan 1 was irradiated at 0° and 180° for 16 RT sessions. The dosage was increased to 3 Gy for Plan 2 for 4 sessions. Plan 3 used 2 Gy with 6 and 8 megavolt photons, and Plan 3 was irradiated at 27.7° and 200.7° for 11 RT sessions. Changes in measured parameters were assessed before and after RT.Changes in impedance of LV and high-voltage lead exceeded prespecified threshold. However, no significant errors were detected in the CRTD on the dosages and energy we used.We hypothesize that the lead insulator could have been affected by radiation.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Cardiac Resynchronization Therapy Devices , Cardiomyopathy, Dilated/therapy , Defibrillators, Implantable , Lung Neoplasms/radiotherapy , Radiotherapy/methods , Aged , Carcinoma, Squamous Cell/complications , Cardiac Resynchronization Therapy , Cardiomyopathy, Dilated/complications , Electric Impedance , Electrodes, Implanted , Humans , Lung Neoplasms/complications , Male
2.
PLoS One ; 13(10): e0202247, 2018.
Article in English | MEDLINE | ID: mdl-30379815

ABSTRACT

OBJECTIVE: We investigated the effects of a single instance of caffeine intake on neurocognitive functions and driving performance in healthy subjects using an established cognitive battery and a driving simulator system. METHODS: This study was conducted in a double-blind, randomized, placebo-controlled manner from February 19, 2016 to August 6, 2016. Caffeine intake was discontinued 3 days prior to the study. Participants were randomly assigned to receive 200-mg doses of caffeine or a placebo. Thirty minutes after administration, cognitive functions were evaluated via the Symbol Digit Coding Test (SDC), the Stroop Test (ST), the Shifting Attention Test (SAT) and the Four Part Continuous Performance Test (FPCPT). After the cognitive function tests were conducted, driving performance was evaluated using a driving simulator. We measured the brake reaction time (BRT) in the Harsh-braking test and the standard deviation of the lateral position (SDLP) in the Road-tracking test. RESULTS: Of 100 randomized subjects, 50 (50%) of 100 in the caffeine group and 50 (50%) of 100 in the placebo group completed the study. Participants in the caffeine group had more correct responses than participants in the placebo group on the SAT (P = 0.03) and made fewer errors (P = 0.02). Participants in the caffeine group exhibited shorter times in the Harsh-braking test than participants in the placebo group (P = 0.048). CONCLUSIONS: A single instance of caffeine intake changed some neurocognitive functions and driving performance in healthy volunteers. TRIAL REGISTRATION: UMIN000023576.


Subject(s)
Attention/drug effects , Caffeine/administration & dosage , Cognition/drug effects , Psychomotor Performance/drug effects , Adult , Attention/physiology , Cognition/physiology , Double-Blind Method , Female , Healthy Volunteers , Humans , Male , Middle Aged , Neuropsychology , Psychomotor Performance/physiology , Reaction Time/drug effects
4.
Psychiatry Clin Neurosci ; 72(9): 713-722, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29845681

ABSTRACT

AIM: We aimed to examine the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and suicidal behavior in psychiatric outpatients and whether this association differs among patients with different psychiatric disorders. METHODS: Cross-sectional data came from the Japan Prevalence Study of Adult ADHD at Psychiatric Outpatient Care, which included psychiatric outpatients aged 18-65 years recruited from one university hospital and three general psychiatric outpatient clinics in Kitakyushu City, Fukuoka, Japan from April 2014 to January 2015 (N = 864). The Adult ADHD Self-Report Scale (ASRS) Screener was used to collect information on ADHD symptoms. Reports of current and lifetime suicidal behavior were also obtained. A multivariable Poisson regression analysis was used to examine the association between ADHD symptoms and suicidal behavior. RESULTS: After adjusting for covariates there was a strong association between possible ADHD (ASRS ≥14) and suicidal behavior with prevalence ratios ranging from 1.17 (lifetime suicidal ideation) to 1.59 (lifetime suicide attempt) and 2.36 (current suicidal ideation). When ASRS strata were used, there was a dose-response association between increasing ADHD symptoms and suicidal ideation and suicide attempts. Analyses of individual ICD-10 psychiatric disorders showed that associations varied across disorders and that for anxiety disorder, ADHD symptoms were significantly linked to all forms of suicidal behavior. CONCLUSION: ADHD symptom severity is associated with an increased risk for suicidal behavior in general psychiatric outpatients. As ADHD symptoms are common among adult psychiatric outpatients, detecting and treating ADHD in this population may be important for preventing suicidal behavior.


Subject(s)
Attention Deficit Disorder with Hyperactivity/epidemiology , Mental Disorders/epidemiology , Suicidal Ideation , Suicide, Attempted/statistics & numerical data , Adolescent , Adult , Aged , Attention Deficit Disorder with Hyperactivity/complications , Attention Deficit Disorder with Hyperactivity/diagnosis , Comorbidity , Cross-Sectional Studies , Female , Humans , Japan/epidemiology , Male , Mental Disorders/diagnosis , Middle Aged , Outpatients , Prevalence , Young Adult
5.
Respir Care ; 63(3): 267-273, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29432140

ABSTRACT

BACKGROUND: High-flow nasal cannula (HFNC) oxygen therapy produces noise at a level such that patients often complain. However, the noise level has not been measured digitally. METHODS: We evaluated 3 types of HFNCs without filters and 2 types with filters attached for noise reduction. Optiflow (with and without a filter), MaxVenturi (with and without a filter) and AIRVO2 (without a filter only) were positioned at the center of a hospital room. We measured the noise levels at the distance of 1 m from the equipment at various total flows (30, 40, 50, 60 L/min) and FIO2 (0.40, 0.60, and 0.90). RESULTS: Noise levels were increased with the AIRVO2 and MaxVenturi when total flow and FIO2 were increased. Noise levels decreased with the MaxVenturi when a filter was used. The noise level did not change with the Optiflow when total flow and FIO2 were increased. The noise level decreased in the groups with AIRVO2 and Optiflow compared with MaxVenturi without a filter. CONCLUSIONS: The findings in this study show that the noise level of HFNC/Venturi could be reduced by attaching an intake filter. However, the noise level of HFNC/blender and HFNC/turbine decreased in comparison with HFNC/Venturi without an intake filter.


Subject(s)
Cannula , Noise/prevention & control , Oxygen Inhalation Therapy/instrumentation , Oxygen/administration & dosage , Health Facility Environment , Oxygen Inhalation Therapy/methods
7.
Schizophr Res Cogn ; 6: 9-14, 2016 Dec.
Article in English | MEDLINE | ID: mdl-28740819

ABSTRACT

The Specific Levels of Functioning Scale (SLOF) has been reported to provide a measure of social function in patients with schizophrenia. The aim of this multi-center study was to determine convergent validity of the Japanese version of SLOF, and if cognitive insight would be associated with social function. Fifty-eight patients with schizophrenia participated in the study. Social function, neurocognition, and daily activity skills were evaluated by the Social Functioning Scale (SFS), Brief Assessment of Cognition in Schizophrenia (BACS) and UCSD Performance-based Skills Assessment-Brief (UPSA-B), respectively. We also assessed cognitive insight with the Beck Cognitive Insight Scale (BCIS). Significant relationships were noted between scores on the SLOF vs. those of the SFS, BACS, UPSA-B, and BCIS. Specifically, the correlation between performance on the UPSA-B and SLOF scores was significantly more robust compared to the correlation between performance on the UPSA-B and scores on the SFS. Similarly, the correlation between scores on the BACS and SLOF tended to be more robust than that between the BACS and SFS. Importantly, while the correlation between scores on the BCIS and SLOF reached significance, it was not so between scores on the BCIS and SFS. The SLOF Japanese version was found to provide a measure of social consequences in patients with schizophrenia. Importantly, this study is the first to indicate the relationship between cognitive insight and social function evaluated by the SLOF. This finding is consistent with the observation that SLOF scores were considerably associated with performances on objective functional measures.

SELECTION OF CITATIONS
SEARCH DETAIL